Molecular Features Predicting Response/Resistance to Trastuzumab in Metastatic Breast Cancer Patients

Plain-language summary

This study examined molecular features that might predict response or resistance to Trastuzumab in patients with metastatic breast cancer, using gene mutation analyses and FISH. It was open to patients with a breast cancer diagnosis whose tumor tissue and Trastuzumab response could be assessed. Run by Istituto Clinico Humanitas, it was a study without an assigned phase and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Completed

Sponsor

Istituto Clinico Humanitas

Intervention

Gene mutation analyses and FISH

Start date

10/1/2007

Estimated completion

8/1/2010

Countries

Italy

Related genes

Locations

• Rozzano, Italy

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Hystological diagnosis of breast cancer
* Availability of tumor tissue
* Availability to assess the response to Trastuzumab according to RECIST criteria
* Availability of clinical data

Exclusion Criteria:

* Unavailability of tumor tissue
* Impossibility to assess the response to Trastuzumab according to RECIST criteria